| Adaptive designs in clinical trials: why use them, and how to run and report them P Pallmann, AW Bedding, B Choodari-Oskooei, M Dimairo, L Flight, ... BMC medicine 16, 1-15, 2018 | 581 | 2018 |
| DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial JA Cook, SA Julious, W Sones, LV Hampson, C Hewitt, JA Berlin, ... bmj 363, 2018 | 202 | 2018 |
| Bayesian methods for the design and interpretation of clinical trials in very rare diseases LV Hampson, J Whitehead, D Eleftheriou, P Brogan Statistics in medicine 33 (24), 4186-4201, 2014 | 108 | 2014 |
| Minimizing patient burden through the use of historical subject-level data in innovative confirmatory clinical trials: review of methods and opportunities J Lim, R Walley, J Yuan, J Liu, A Dabral, N Best, A Grieve, L Hampson, ... Therapeutic innovation & regulatory science 52, 546-559, 2018 | 100 | 2018 |
| A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma N Cook, B Basu, DM Smith, A Gopinathan, J Evans, WP Steward, ... British journal of cancer 118 (6), 793-801, 2018 | 96 | 2018 |
| Group sequential tests for delayed responses (with discussion) LV Hampson, C Jennison Journal of the Royal Statistical Society Series B: Statistical Methodology …, 2013 | 85 | 2013 |
| “Threshold‐crossing”: a useful way to establish the counterfactual in clinical trials? HG Eichler, B Bloechl‐Daum, P Bauer, F Bretz, J Brown, LV Hampson, ... Clinical Pharmacology & Therapeutics 100 (6), 699-712, 2016 | 83 | 2016 |
| Efficient adaptive designs for clinical trials of interventions for COVID-19 N Stallard, L Hampson, N Benda, W Brannath, T Burnett, T Friede, ... Statistics in Biopharmaceutical Research 12 (4), 483-497, 2020 | 62 | 2020 |
| Extrapolation of efficacy and other data to support the development of new medicines for children: a systematic review of methods I Wadsworth, LV Hampson, T Jaki Statistical Methods in Medical Research 27 (2), 398-413, 2018 | 50 | 2018 |
| Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa LV Hampson, J Whitehead, D Eleftheriou, C Tudur-Smith, R Jones, ... PLoS One 10 (3), e0120981, 2015 | 50 | 2015 |
| Aquatic therapy for children with Duchenne muscular dystrophy: a pilot feasibility randomised controlled trial and mixed-methods process evaluation. D Hind, J Parkin, V Whitworth, S Rex, T Young, L Hampson, J Sheehan, ... Health technology assessment (Winchester, England) 21 (27), 1, 2017 | 35 | 2017 |
| Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly … C Brard, S Piperno-Neumann, J Delaye, L Brugières, LV Hampson, ... BMJ open 9 (5), e025877, 2019 | 32 | 2019 |
| Cost–utility analysis conducted alongside randomized controlled trials: Are economic end points considered in sample size calculations and does it matter? W Hollingworth, D McKell-Redwood, L Hampson, C Metcalfe Clinical Trials 10 (1), 43-53, 2013 | 32 | 2013 |
| Bayesian survival analysis in clinical trials: What methods are used in practice? C Brard, G Le Teuff, MC Le Deley, LV Hampson Clinical Trials 14 (1), 78-87, 2017 | 31 | 2017 |
| Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: an example of a proposed trial of adalimumab versus pamidronate for … AV Ramanan, LV Hampson, H Lythgoe, AP Jones, B Hardwick, H Hind, ... PLoS One 14 (6), e0215739, 2019 | 27 | 2019 |
| Aquatic therapy for boys with Duchenne muscular dystrophy (DMD): an external pilot randomised controlled trial D Hind, J Parkin, V Whitworth, S Rex, T Young, L Hampson, J Sheehan, ... Pilot and Feasibility Studies 3, 1-17, 2017 | 27 | 2017 |
| Exercise and self-management for people with chronic knee, hip or lower back pain: a cluster randomised controlled trial of clinical and cost-effectiveness. Study protocol N Walsh, F Cramp, S Palmer, J Pollock, L Hampson, R Gooberman-Hill, ... Physiotherapy 99 (4), 352-357, 2013 | 24 | 2013 |
| A Bayesian approach for dose-escalation in a phase I clinical trial incorporating pharmacodynamic endpoints J Whitehead, Y Zhou, L Hampson, E Ledent, A Pereira Journal of Biopharmaceutical statistics 17 (6), 1117-1129, 2007 | 24 | 2007 |
| Estimands and the patient journey: addressing the right question in oncology clinical trials E Degtyarev, Y Zhang, K Sen, D Lebwohl, M Akacha, LV Hampson, ... JCO Precision Oncology 3, 1-10, 2019 | 22 | 2019 |
| Biostatistical considerations when using RWD and RWE in clinical studies for regulatory purposes: a landscape assessment M Levenson, W He, J Chen, Y Fang, D Faries, BA Goldstein, M Ho, K Lee, ... Statistics in Biopharmaceutical Research 15 (1), 3-13, 2023 | 20 | 2023 |
